VIRGINIA CAFARO: Open Payments
NPI 1174596969 · SAN FRANCISCO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,822 in 127 payments from 23 companies in 2025. Trend: 2023 $11,497 · 2024 $5,631 · 2025 $2,822
Food & beverage: $2,822
| Company | Payments | Amount |
|---|---|---|
| ViiV Healthcare Company | 34 | $559 |
| Gilead Sciences, Inc. | 17 | $381 |
| ABBVIE INC. | 15 | $318 |
| AstraZeneca Pharmaceuticals LP | 9 | $230 |
| Novo Nordisk Inc | 7 | $177 |
| Merck Sharp & Dohme LLC | 6 | $167 |
| PFIZER INC. | 5 | $142 |
| Theratechnologies Inc. | 5 | $138 |
| Lilly USA, LLC | 4 | $111 |
| Astellas Pharma US Inc | 4 | $106 |
Products named: DOVATO, AIRSUPRA, PIFELTRO, RUKOBIA, EGRIFTA, APRETUDE, VRAYLAR, Veozah.
Industry payments across CA — which companies pay providers there.
